Recent Research Analysts’ Ratings Updates for Teva Pharmaceutical Industries (TEVA)

by · The Cerbat Gem

Teva Pharmaceutical Industries (NYSE: TEVA) has recently received a number of price target changes and ratings updates:

  • 12/9/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at Bank of America Corporation from $29.00 to $32.00. They now have a “buy” rating on the stock.
  • 12/9/2025 – Teva Pharmaceutical Industries is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $35.00 price target on the stock.
  • 12/8/2025 – Teva Pharmaceutical Industries was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
  • 12/8/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a “buy” rating on the stock.
  • 12/5/2025 – Teva Pharmaceutical Industries is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $35.00 price target on the stock.
  • 11/6/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $28.00. They now have an “overweight” rating on the stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the sale, the insider owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also